Topical clindamycin for acne vulgaris: analysis of gastrointestinal events

References

• Del Rosso JQ, Schmidt NF. A review of the anti-inflammatory properties of clindamycin in the treatment of acne vulgaris. Cutis. 2010;85(1):1–7.
   Web of Science ®Google Scholar
• American Chemical Society. 2022. Molecule of the week archive: clindamycin; [cited 2023 May 01]. Available from: https://www.acs.org/molecule-of-the-week/archive/c/clindamycin.html
   Google Scholar
• The Center for Drug Evaluation and Research and The US Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs; [cited 2023 May 18]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/
   Google Scholar
• Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945.e33–973.e33. doi: 10.1016/j.jaad.2015.12.037.
   Web of Science ®Google Scholar
• Dallo M, Patel K, Hebert AA. Topical antibiotic treatment in dermatology. Antibiotics. 2023;12(2):188. doi: 10.3390/antibiotics12020188.
   Google Scholar
• CLEOCIN-T® [monograph]. New York (NY): Pfizer; 2019.
   Google Scholar
• CLINDAGEL® [monograph]. Santa Rosa (CA): Clindagel, LLC; 2000.
   Google Scholar
• EVOCLIN® [package insert]. Morgantown (WV): Mylan Pharmaceuticals; 2010.
   Google Scholar
• CLEOCIN HCl® [package insert]. New York (NY): Pfizer; 2022.
   Google Scholar
• Nielson C, Hsu S, Motaparthi K. Topical antibacterial agents. In: Wolverton S, Wi J, editors. Comprehensive dermatologic drug therapy. 4th ed. Philadelphia (PA): Elsevier; 2021. p. 474–475.
   Google Scholar
• Abdulla H, Shalita A. Topical clindamycin preparations in the treatment of acne vulgaris. Expert Rev Dermatol. 2009;4(2):155–162. doi: 10.1586/edm.09.3.
   Google Scholar
• Mavranezouli I, Daly CH, Welton NJ, et al. A systematic review and network meta-analysis of topical pharmacological, oral pharmacological, physical and combined treatments for acne vulgaris. Br J Dermatol. 2022;187(5):639–649. doi: 10.1111/bjd.21739.
   PubMed Web of Science ®Google Scholar
• Schlessinger J, Menter A, Gold M, et al. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6(6):607–615.
   PubMedGoogle Scholar
• Kircik LH, Peredo MI, Bucko AD, et al. Safety of a novel gel formulation of clindamycin phosphate 1.2%-tretinoin 0.025%: results from a 52-week open-label study. Cutis. 2008;82(5):358–366.
   PubMed Web of Science ®Google Scholar
• Leyden J, Wortzman M, Baldwin EK. Tolerability of clindamycin/tretinoin gel vs. tretinoin microsphere gel and adapalene gel. J Drugs Dermatol. 2009;8(4):383–388.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Wortzman M. A novel gel formulation of 0.25% tretinoin and 1.2% clindamycin phosphate: efficacy in acne vulgaris patients aged 12 to 18 years. Pediatr Dermatol. 2009;26(3):257–261. doi: 10.1111/j.1525-1470.2008.00862.x.
   PubMed Web of Science ®Google Scholar
• Callender VD, Young CM, Kindred C, et al. Efficacy and safety of clindamycin phosphate 1.2% and tretinoin 0.025% gel for the treatment of acne and acne-induced post-inflammatory hyperpigmentation in patients with skin of color. J Clin Aesthet Dermatol. 2012;5(7):25–32.
   PubMedGoogle Scholar
• Del Rosso JQ. Clindamycin phosphate 1.2%/tretinoin 0.025% gel for the treatment of acne vulgaris: which patients are most likely to benefit the most? J Clin Aesthet Dermatol. 2015;8(6):19–23.
   Google Scholar
• Barza M, Goldstein JA, Kane A, et al. Systemic absorption of clindamycin hydrochloride after topical application. J Am Acad Dermatol. 1982;7(2):208–214. doi: 10.1016/s0190-9622(82)70109-4.
   PubMed Web of Science ®Google Scholar
• Eller MG, Smith RB, Phillips JP. Absorption kinetics of topical clindamycin preparations. Biopharm Drug Dispos. 1989;10(5):505–512. doi: 10.1002/bdd.2510100508.
   PubMed Web of Science ®Google Scholar
• Mazur D, Schug BS, Evers G, et al. Bioavailability and selected pharmacokinetic parameters of clindamycin hydrochloride after administration of a new 600 mg tablet formulation. Int J Clin Pharmacol Ther. 1999;37(8):386–392.
   PubMed Web of Science ®Google Scholar
• van Hoogdalem EJ. Transdermal absorption of topical anti-acne agents in man; review of clinical pharmacokinetic data. J Eur Acad Dermatol Venereol. 1998;11 Suppl 1: s13–s19; discussion S28–S29. doi: 10.1111/j.1468-3083.1998.tb00902.x.
   PubMed Web of Science ®Google Scholar
• Franz TJ. On the bioavailability of topical formulations of clindamycin hydrochloride. J Am Acad Dermatol. 1983;9(1):66–73. doi: 10.1016/s0190-9622(83)70108-8.
   PubMed Web of Science ®Google Scholar
• van Hoogdalem EJ, Baven TL, Spiegel-Melsen I, et al. Transdermal absorption of clindamycin and tretinoin from topically applied anti-acne formulations in man. Biopharm Drug Dispos. 1998;19(9):563–569. doi: 10.1002/(SICI)1099-081X(199812)19:9<563::AID-BDD134>3.0.CO;2-E.
   PubMed Web of Science ®Google Scholar
• Chassard D, Kanis R, Namour F, et al. A single Centre, open-label, cross-over study of pharmacokinetics comparing topical zinc/clindamycin gel (zindaclin) and topical clindamycin lotion (dalacin T) in subjects with mild to moderate acne. J Dermatolog Treat. 2006;17(3):154–157. doi: 10.1080/09546630600727115.
   PubMed Web of Science ®Google Scholar
• Walsh TR, Efthimiou J, Dréno B. Systematic review of antibiotic resistance in acne: an increasing topical and oral threat. Lancet Infect Dis. 2016;16(3):e23–e33. doi: 10.1016/S1473-3099(15)00527-7.
   PubMed Web of Science ®Google Scholar
• Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the global alliance to improve outcomes in acne group. J Am Acad Dermatol. 2009;60(5 Suppl):S1–S50. doi: 10.1016/j.jaad.2009.01.019.
   PubMed Web of Science ®Google Scholar
• Leyden JJ, Hickman JG, Jarratt MT, et al. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg. 2001;5(1):37–42. doi: 10.1177/120347540100500109.
   PubMed Web of Science ®Google Scholar
• Cunliffe WJ, Holland KT, Bojar R, et al. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther. 2002;24(7):1117–1133. doi: 10.1016/s0149-2918(02)80023-6.
   PubMed Web of Science ®Google Scholar
• Leyden JJ, Wortzman M, Baldwin EK. Antibiotic-resistant Propionibacterium acnes suppressed by a benzoyl peroxide cleanser 6%. Cutis. 2008;82(6):417–421.
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Gamal A, Kadry A, et al. Avoiding the danger of rising resistance in Cutibacterium acnes: criticality of benzoyl peroxide and antibiotic fixed combinations. J Amer Acad Dermatol. 2023;89(3);Supplement AB20.
   Google Scholar
• Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology. 2014;146(6):1547–1553. doi: 10.1053/j.gastro.2014.01.059.
   PubMed Web of Science ®Google Scholar
• Buffie CG, Jarchum I, Equinda M, et al. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun. 2012;80(1):62–73. doi: 10.1128/IAI.05496-11.
   PubMed Web of Science ®Google Scholar
• Borglund E, Hägermark O, Nord CE. Impact of topical clindamycin and systemic tetracycline on the skin and Colon microflora in patients with acne vulgaris. Scand J Infect Dis Suppl. 1984;43:76–81.
   PubMedGoogle Scholar
• Siegle RJ, Fekety R, Sarbone PD, et al. Effects of topical clindamycin on intestinal microflora in patients with acne. J Am Acad Dermatol. 1986;15(2 Pt 1):180–185. doi: 10.1016/s0190-9622(86)70153-9.
   PubMed Web of Science ®Google Scholar
• Parry MF, Rha CK. Pseudomembranous colitis caused by topical clindamycin phosphate. Arch Dermatol. 1986;122(5):583–584. doi: 10.1001/archderm.1986.01660170113031.
   PubMedGoogle Scholar
• Milstone EB, McDonald AJ, Scholhamer CF Jr. Pseudo­membranous colitis after topical application of clindamycin. Arch Dermatol. 1981;117(3):154–155. doi: 10.1001/archderm.1981.01650030032015.
   PubMedGoogle Scholar
• Schiedermayer DL, Loo FD. Topical clindamycin-associated diarrhea. Case report and review of the literature. Wis Med J. 1987;86(3):29–30.
   PubMedGoogle Scholar
• Gallerani M, Ricci L, Calò G, et al. Abdominal pain and diarrhoea caused by topical clindamycin phosphate. Clin Drug Investig. 1997;14(3):243–245. doi: 10.2165/00044011-199714030-00013.
   Web of Science ®Google Scholar
• Ventola CL. Big data and pharmacovigilance: data mining for adverse drug events and interactions. Pharm Ther. 2018;43(6):340–351.
   Google Scholar
• Stergachis A, Perera DR, Schnell MM, et al. Antibiotic-associated colitis. West J Med. 1984;140(2):217–219.
   PubMedGoogle Scholar
• Watson Health. The IBM Explorys platform: liberate your healthcare data; [cited 2023 May 18]. Available from: https://www.ibm.com/downloads/cas/4P0QB9JN
   Google Scholar
• Thiboutot D, Zaenglein A, Weiss J, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol. 2008;59(5):792–800. doi: 10.1016/j.jaad.2008.06.040.
   PubMed Web of Science ®Google Scholar
• Pariser DM, Rich P, Cook-Bolden FE, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris. J Drugs Dermatol. 2014;13(9):1083–1089.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. NDA-050-741. 2002; [cited 2023 May 01]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50-741_DUAC%20Topical%20Gel_Medr_P1.pdf
   Google Scholar
• US Food and Drug Administration. NDA-050-803. 2010; [cited 2023 May 01]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/050803Orig1s000MedR.pdf
   Google Scholar
• US Food and Drug Administration. NDA-050-801. 2004; [cited 2023 May 03]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/050801s000_Evoclin_MedR.pdf
   Google Scholar
• Data on file, Bausch Health Americas, Inc. Studies V01-126A-301 and V01-126A-302.
   Google Scholar